|
Q3 FY2026
As of Jun 30, 2026
|
Q2 FY2026
As of Mar 31, 2026
|
Q1 FY2026
As of Dec 31, 2025
|
Q4 FY2025
As of Sep 30, 2025
|
Q3 FY2025
As of Jun 30, 2025
|
Q2 FY2025
As of Mar 31, 2025
|
Q1 FY2025
As of Dec 31, 2024
|
Q4 FY2024
As of Sep 30, 2024
|
Q3 FY2024
As of Jun 30, 2024
|
Q2 FY2024
As of Mar 31, 2024
|
Q1 FY2024
As of Dec 31, 2023
|
Q4 FY2023
As of Sep 30, 2023
|
Q3 FY2023
As of Jun 30, 2023
|
Q2 FY2023
As of Mar 31, 2023
|
Q1 FY2023
As of Dec 31, 2022
|
Q4 FY2022
As of Sep 30, 2022
|
Q3 FY2022
As of Jun 30, 2022
|
Q2 FY2022
As of Mar 31, 2022
|
Q1 FY2022
As of Dec 31, 2021
|
Q4 FY2021
As of Sep 30, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current assets: | ||||||||||||||||||||
| Cash and cash equivalents | ||||||||||||||||||||
| Accounts receivable, net of allowance for credit losses of $268,948 and $42,180, respectively | ||||||||||||||||||||
| Accounts receivable, net | ||||||||||||||||||||
| Accounts receivable – discontinued operations | ||||||||||||||||||||
| Investment other securities | ||||||||||||||||||||
| Inventory | ||||||||||||||||||||
| Inventory prepaid | ||||||||||||||||||||
| Prepaid sponsorship | ||||||||||||||||||||
| Prepaid expenses and other current assets | ||||||||||||||||||||
| Total current assets | ||||||||||||||||||||
| Other assets: | ||||||||||||||||||||
| Property and equipment, net | ||||||||||||||||||||
| Operating lease assets | ||||||||||||||||||||
| Deposits for facilities | ||||||||||||||||||||
| Intangible assets, net | ||||||||||||||||||||
| Goodwill | ||||||||||||||||||||
| Investment in other securities, noncurrent | ||||||||||||||||||||
| Total other assets | ||||||||||||||||||||
| Total assets | ||||||||||||||||||||
| Current liabilities: | ||||||||||||||||||||
| Accounts payable | ||||||||||||||||||||
| Accrued expenses | ||||||||||||||||||||
| Accrued dividends | ||||||||||||||||||||
| Deferred revenue | ||||||||||||||||||||
| Operating leases – current portion | ||||||||||||||||||||
| Convertible notes, at fair value | ||||||||||||||||||||
| Note payable | ||||||||||||||||||||
| Total current liabilities | ||||||||||||||||||||
| Long term liabilities: | ||||||||||||||||||||
| Convertible notes | ||||||||||||||||||||
| Other long term liabilities | ||||||||||||||||||||
| Long term liabilities | ||||||||||||||||||||
| Operating leases - long term portion | ||||||||||||||||||||
| Contingent liability | ||||||||||||||||||||
| Total long term liabilities: | ||||||||||||||||||||
| Total liabilities | ||||||||||||||||||||
| cbdMD, Inc. shareholders' equity: | ||||||||||||||||||||
| Preferred Stock | ||||||||||||||||||||
| Common Stock | ||||||||||||||||||||
| Additional paid in capital | ||||||||||||||||||||
| Comprehensive other expense | ||||||||||||||||||||
| Accumulated deficit | ||||||||||||||||||||
| Total cbdMD, Inc. shareholders' equity | ||||||||||||||||||||
| Total liabilities and shareholders' equity | ||||||||||||||||||||
Loading...
